Transarterial Chemoembolization(TACE)

DEVICE4 trials

Sponsors

Fudan University, The First Affiliated Hospital of Dalian Medical University, Beijing Ditan Hospital, Peking Union Medical College Hospital

Conditions

Carcinoma, HepatocellularHepatocellular CarcinomaLiver CancerPortal Vein Tumor Thrombus

Phase 1

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

RecruitingNCT05842317

Peking Union Medical College HospitalHepatocellular Carcinoma

Start: 2022-09-01End: 2024-11-15Target: 60Updated: 2024-02-09

Phase 2

Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

Fudan UniversityHepatocellular Carcinoma

Start: 2019-09-03End: 2022-08-01Target: 300Updated: 2020-07-28

Phase 4

Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver Cancer

The First Affiliated Hospital of Dalian Medical UniversityLiver Cancer

Start: 2019-01-27End: 2020-09-01Target: 90Updated: 2019-02-18

Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

Beijing Ditan HospitalCarcinoma, Hepatocellular, Portal Vein Tumor Thrombus

Start: 2019-09-01End: 2021-12-01Target: 72Updated: 2021-07-23

Related Papers

Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, non-randomized, open-label, phase II cohort study.

Journal of Clinical Oncology2024-06-01

Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study

Cancer2021-07-08136 citations